Clinical trial
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced…
NCT00416533 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00416533 |
|---|---|
| Title | Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, doxorubicin hydrochloride, prednisone |
| Enrollment | 47 |
| Start date | Aug 1, 2004 |
| Primary completion | Oct 1, 2006 |
| First posted | Dec 28, 2006 |
| Last update posted | Jan 19, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: